MA47356A1 - Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases - Google Patents
Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinasesInfo
- Publication number
- MA47356A1 MA47356A1 MA47356A MA47356A MA47356A1 MA 47356 A1 MA47356 A1 MA 47356A1 MA 47356 A MA47356 A MA 47356A MA 47356 A MA47356 A MA 47356A MA 47356 A1 MA47356 A1 MA 47356A1
- Authority
- MA
- Morocco
- Prior art keywords
- kinases
- phosphoinositide
- inhibitors
- derivatives useful
- isochromene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
- C07D473/38—Sulfur atom attached in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La présente invention concerne des composés qui inhibent les phosphoinositide 3-kinases (pi3k), des compositions pharmaceutiques comprenant ces composés et l'utilisation thérapeutique de celles-ci dans le traitement des maladies associées aux enzymes pi3k.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13197986 | 2013-12-18 | ||
PCT/EP2014/078288 WO2015091685A1 (fr) | 2013-12-18 | 2014-12-17 | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
MA47356A1 true MA47356A1 (fr) | 2020-10-28 |
MA47356B1 MA47356B1 (fr) | 2021-03-31 |
Family
ID=49841547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA47356A MA47356B1 (fr) | 2013-12-18 | 2014-12-17 | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases |
Country Status (34)
Country | Link |
---|---|
US (1) | US9321776B2 (fr) |
EP (1) | EP3083617B1 (fr) |
JP (1) | JP6617973B2 (fr) |
KR (1) | KR102371570B1 (fr) |
CN (1) | CN105829308B (fr) |
AR (1) | AR098776A1 (fr) |
AU (1) | AU2014368725B2 (fr) |
CA (1) | CA2934135C (fr) |
CL (1) | CL2016001543A1 (fr) |
CY (1) | CY1122098T1 (fr) |
DK (1) | DK3083617T3 (fr) |
EA (1) | EA035173B1 (fr) |
ES (1) | ES2755355T3 (fr) |
GE (1) | GEP20196954B (fr) |
HR (1) | HRP20192151T1 (fr) |
HU (1) | HUE046470T2 (fr) |
IL (1) | IL246263B (fr) |
LT (1) | LT3083617T (fr) |
MA (1) | MA47356B1 (fr) |
MX (1) | MX370900B (fr) |
MY (1) | MY181602A (fr) |
PE (1) | PE20160689A1 (fr) |
PH (1) | PH12016501160A1 (fr) |
PL (1) | PL3083617T3 (fr) |
PT (1) | PT3083617T (fr) |
RS (1) | RS59720B1 (fr) |
SA (1) | SA516371350B1 (fr) |
SG (1) | SG11201604908UA (fr) |
SI (1) | SI3083617T1 (fr) |
TN (1) | TN2016000245A1 (fr) |
TW (1) | TWI672297B (fr) |
UA (1) | UA120751C2 (fr) |
WO (1) | WO2015091685A1 (fr) |
ZA (1) | ZA201604084B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
BR112016007467B1 (pt) | 2013-10-04 | 2022-09-20 | Infinity Pharmaceuticals, Inc | Compostos heterocíclicos e usos dos mesmos |
CN113620958A (zh) | 2014-03-19 | 2021-11-09 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US9968604B2 (en) | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
CA2998469A1 (fr) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Formes solides d'isoquinoleines, procedes de fabrication, composition les comprenant et methodes d'utilisation |
WO2017134053A1 (fr) | 2016-02-04 | 2017-08-10 | Chiesi Farmaceutici S.P.A. | Dérivés de pyrazole à utiliser en tant qu'inhibiteurs de phosphoinositide 3-kinases |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2017214269A1 (fr) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
CN108623573A (zh) * | 2017-03-16 | 2018-10-09 | 河北农业大学 | 一种异香豆素衍生物及其合成方法 |
GB201706102D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US20210370007A1 (en) | 2018-10-30 | 2021-12-02 | Chiesi Farmaceuticl S.p.A. | Apparatus to administer drugs to mechanically ventilated patients |
CA3135309A1 (fr) | 2019-04-04 | 2020-10-08 | Chiesi Farmaceutici S.P.A. | Derives d'isochromene utilises en tant qu'inhibiteurs de phosphoinositide 3-kinases |
JP2022549445A (ja) | 2019-09-24 | 2022-11-25 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 吸入用乾燥粉末製剤のための新規担体粒子 |
CN114195818B (zh) * | 2021-12-24 | 2023-11-24 | 盐城工学院 | 一种4-芳硫基香豆素类化合物及其制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0597841A (ja) * | 1991-10-04 | 1993-04-20 | Mercian Corp | イソクマリン誘導体 |
US5482967A (en) * | 1992-09-04 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
JP3724818B2 (ja) * | 1992-09-04 | 2005-12-07 | 武田薬品工業株式会社 | 縮合複素環化合物、その製造法および剤 |
US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
JP2002161091A (ja) * | 2000-11-28 | 2002-06-04 | Mercian Corp | 気管支拡張剤 |
PT1557414E (pt) * | 2002-10-01 | 2012-04-17 | Mitsubishi Tanabe Pharma Corp | Compostos de isoquinolina e sua utilização medicinal |
KR101653842B1 (ko) * | 2008-01-04 | 2016-09-02 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
LT2496567T (lt) * | 2009-11-05 | 2017-11-27 | Rhizen Pharmaceuticals S.A. | Nauji benzopirano kinazės moduliatoriai |
RS58326B1 (sr) * | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S A | Nova jedinjenja kao modulatori proteinskih kinaza |
US8969363B2 (en) * | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2842190A1 (fr) * | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Composes heterocycliques et leurs utilisations |
WO2016166329A1 (fr) * | 2015-04-17 | 2016-10-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Analyse par cytométrie en flux pour mesurer l'adhésion des upec aux cellules épithéliales de la vessie |
-
2014
- 2014-12-16 TW TW103143808A patent/TWI672297B/zh active
- 2014-12-16 AR ARP140104690A patent/AR098776A1/es active IP Right Grant
- 2014-12-17 SI SI201431363T patent/SI3083617T1/sl unknown
- 2014-12-17 MA MA47356A patent/MA47356B1/fr unknown
- 2014-12-17 PL PL14823973T patent/PL3083617T3/pl unknown
- 2014-12-17 WO PCT/EP2014/078288 patent/WO2015091685A1/fr active Application Filing
- 2014-12-17 ES ES14823973T patent/ES2755355T3/es active Active
- 2014-12-17 PT PT148239734T patent/PT3083617T/pt unknown
- 2014-12-17 CN CN201480068937.0A patent/CN105829308B/zh active Active
- 2014-12-17 HU HUE14823973A patent/HUE046470T2/hu unknown
- 2014-12-17 GE GEAP201414179A patent/GEP20196954B/en unknown
- 2014-12-17 MY MYPI2016001125A patent/MY181602A/en unknown
- 2014-12-17 LT LT14823973T patent/LT3083617T/lt unknown
- 2014-12-17 DK DK14823973T patent/DK3083617T3/da active
- 2014-12-17 US US14/573,887 patent/US9321776B2/en active Active
- 2014-12-17 CA CA2934135A patent/CA2934135C/fr active Active
- 2014-12-17 EP EP14823973.4A patent/EP3083617B1/fr active Active
- 2014-12-17 UA UAA201606598A patent/UA120751C2/uk unknown
- 2014-12-17 MX MX2016007410A patent/MX370900B/es active IP Right Grant
- 2014-12-17 PE PE2016000828A patent/PE20160689A1/es unknown
- 2014-12-17 KR KR1020167018944A patent/KR102371570B1/ko active IP Right Grant
- 2014-12-17 SG SG11201604908UA patent/SG11201604908UA/en unknown
- 2014-12-17 JP JP2016537024A patent/JP6617973B2/ja active Active
- 2014-12-17 TN TN2016000245A patent/TN2016000245A1/en unknown
- 2014-12-17 RS RS20191559A patent/RS59720B1/sr unknown
- 2014-12-17 EA EA201691032A patent/EA035173B1/ru unknown
- 2014-12-17 AU AU2014368725A patent/AU2014368725B2/en active Active
-
2016
- 2016-06-15 ZA ZA2016/04084A patent/ZA201604084B/en unknown
- 2016-06-16 IL IL246263A patent/IL246263B/en active IP Right Grant
- 2016-06-16 SA SA516371350A patent/SA516371350B1/ar unknown
- 2016-06-16 CL CL2016001543A patent/CL2016001543A1/es unknown
- 2016-06-16 PH PH12016501160A patent/PH12016501160A1/en unknown
-
2019
- 2019-10-02 CY CY20191101028T patent/CY1122098T1/el unknown
- 2019-11-29 HR HRP20192151TT patent/HRP20192151T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
MA40290A1 (fr) | Agents immunorégulateurs | |
CO2020001244A2 (es) | Derivados de quinolina para tratar infecciones con helmintos | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
MA41251B1 (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
MA38483A1 (fr) | Inhibiteurs de l'ido | |
EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
MA46490A1 (fr) | Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
BR112016006388A2 (pt) | inibidor seletivo da fosfatidilinositol 3-quinase gama | |
MA38925B1 (fr) | Dérivés de phénylalanine substitués | |
MA38810A1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
CA2929436C (fr) | Composes, composition pharmaceutique et methodes a utiliser dans le traitement de maladies inflammatoires | |
EA201690323A1 (ru) | Способы лечения заболеваний уха у детей | |
MA39171A1 (fr) | Dérivés d'hydroxy formamide et leur utilisation | |
EA201500737A1 (ru) | Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов |